Opendata, web and dolomites

DREAM SIGNED

Dux4-Regulated Expression and Activity by MATR3

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DREAM project word cloud

Explore the words cloud of the DREAM project. It provides you a very rough idea of what is the project "DREAM" about.

myogenic    degeneration    peptidomimetic    domain    cells    hypothesize    dux4    muscle    pro    tools    strategy    indiscriminately    cytotoxic    stages    toxicity    patients    function    double    innovation    action    blocking    clarify    genes    regulates    first    corollary    regulator    activates    tissues    wasting    aberrant    sexes    representing    embryogenesis    identification    mechanism    molecular    interacting    preliminary    binding    stem    prevent    option    silenced    homeobox    afflicts    expression    despite    transcription    therapeutic    activation    data    adults    trials    toxic    characterizing    closer    fshd    protects    examine    muscular    treatment    facioscapulohumeral    rational    matr3    inhibitor    children    preventing    molecule    body    elucidate    dystrophy    block    restricted    transcriptional    pathogenesis    ages    laboratory    models    inhibiting    subjects    compelling    cure    prevalent    mis    caused    treat    direct    disease    healthy    continues    loci    clinical    apoptotic   

Project "DREAM" data sheet

The following table provides information about the project.

Coordinator
OSPEDALE SAN RAFFAELE SRL 

Organization address
address: VIA OLGETTINA 60
city: MILANO
postcode: 20132
website: www.hsr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSPEDALE SAN RAFFAELE SRL IT (MILANO) coordinator 183˙473.00

Map

 Project objective

Facioscapulohumeral muscular dystrophy (FSHD) is the most prevalent muscle disease that indiscriminately afflicts children and adults of all ages and both sexes. Despite several clinical trials, there continues to be no cure or therapeutic option available to FSHD patients. FSHD is caused by aberrant myogenic expression of the transcription factor double homeobox 4 (DUX4). In healthy subjects, DUX4 expression is restricted to stem cells and early stages of embryogenesis while being silenced in most tissues of the body. In FSHD, DUX4 mis-expression activates a pro-apoptotic transcriptional program leading to muscle wasting. Compelling data obtained in our laboratory identified MATR3 as the first direct DUX4 inhibitor and a therapeutic molecule. The identification of a novel regulator of DUX4 function now allows us to examine the potential of inhibiting the cytotoxic activity of DUX4 as a therapeutic strategy to treat FSHD, and represents the innovation of this proposal. The goal of the proposal is to fully elucidate the molecular mechanism through which MATR3 regulates DUX4 function in order to develop novel therapeutic approaches for blocking the aberrant activity of DUX4 in FSHD. Based on our preliminary data, I hypothesize that MATR3 protects from DUX4-induced toxicity by inhibiting DUX4 binding to target loci with the end result of preventing transcriptional activation of genes toxic to muscle cells. Characterizing MATR3 mechanism of action will provide possible therapeutic tools that we will evaluate in relevant models of FSHD. As a corollary, we propose that a peptidomimetic molecule representing the DUX4 interacting domain of MATR3 could be used to prevent the toxic effects of DUX4 expression in muscle cells from FSHD patients. This work is significant as it will clarify the molecular pathogenesis of the disease and bring us closer to a rational treatment to block muscle degeneration in FSHD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DREAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DREAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More